NEW YORK (GenomeWeb) – Genomic informatics firm Cartagenia today announced a partnership to integrate MedGenome's OncoMD Cancer database of clinically actionable cancer variants into its Bench NGS software platform.
MedGenome's OncoMD is a cancer analytics platform that includes proprietary, curated data on 1.7 million cancer mutations, containing relevant functional information, data on drug sensitivity, and lists of potential clinical trials for patient enrollment.
"The combination of our OncoMD cancer knowledge base and Cartagenia's unique software platform offer clinical and pathology laboratories two important tools to allow them to analyze and interpret their own patient data," MedGenome VP of R&D Amit Chaudhuri said in a statement.
In November, Cartagenia signed a deal to integrate the Bench for Oncology software platform with CollabRx's Genetic Variant Annotation service.